000 03538nam a2200445 i 4500
999 _c362832
_d362832
_x1
001 362832
003 ES-MaUEC
005 20230102121622.0
006 a||||fo|||| 00| 0
007 cr nn 008mamaa
008 210518s2021 sz | o |||| 0|eng d
020 _a9783030726768
024 7 _a10.1007/978-3-030-72676-8
_2doi
040 _aES-MaUEC
_bspa
_cES-MaUEC
_dES-MaUEC
050 4 _aRC643
_b2021 EB
245 0 0 _aAcute Myeloid Leukemia
_cedited by Christoph Röllig, Gert J. Ossenkoppele
250 _aFirst edition 2021
264 1 _aCham
_bSpringer International Publishing
_c2021
300 _a1 recurso en línea (VIII, 358 páginas)
_b45 ilustraciones, 40 ilustraciones a color
336 _2rdacontent
_aTexto
_btxt
337 _2rdamedia
_aelectrónico
_bc
338 _2rdacarrier
_arecurso electrónico
_bcr
347 _aArchivo de texto
_bPDF
490 0 _aHematologic Malignancies
_x2197-9774
505 0 _a1. Epidemiology and Etiology -- 2. Diagnosis and Classification of AML: WHO 2016 -- 3. The Genomic Landscape and Clonal Evolution of AML -- 4. Clinical Manifestation and Diagnostic Workup -- 5. Prognostic Factors and Treatment Allocation -- 6. Treatment of Acute Promyelocytic Leukemia -- 7. Treatment of Newly Diagnosed AML in FitPatients -- 8. Treatment of Newly Diagnosed AML in Unfit Patients -- 9. Treatment of Relapsed and Refractory AML -- 10. Allogeneic Stem Cell Transplantation -- 11. Special Clinical Scenarios -- 12. Future Developments.
520 _aThis book, written by a team of leading experts, provides a comprehensive overview of acute myeloid leukemia (AML), the most frequent acute leukemia in adults. The opening chapters present current knowledge of epidemiology, etiologic factors, and the pathogenesis and molecular development of AML. Detailed guidance is offered on laboratory and clinical diagnostic workup and disease classification, and the patient- and disease-related factors that determine prognosis and treatment allocation are identified. On the basis of these general considerations, initial treatments in patients considered fit for intensive treatment and in older and co-morbid patients are reviewed, and the available relapse treatment strategies, explained. For all clinical scenarios, the most recent data on the optimal use of newly approved agents in different AML subgroups are presented. Separate chapters address the treatment of acute promyelocytic leukemia, current practice of allogeneic stem cell transplantation, and special clinical situations. Finally, promising approaches in drug development, current standards and challenges in assessment of measurable residual disease, immune approaches, and ideas for innovative trial designs are considered.
988 _aSpringer_Medicine_2021
650 7 _2embne
_9140673
_aLeucemia
700 1 _aRöllig, Christoph
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aOssenkoppele, Gert J.
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
776 0 8 _iPrinted edition:
_z9783030726751
776 0 8 _iPrinted edition:
_z9783030726775
776 0 8 _iPrinted edition:
_z9783030726782
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-72676-8
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942 _2lcc
_cLE
998 _b02/2022
_dz
_eb
_zSI